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Background
Sentinel-node biopsy, a minimally invasive procedure for regional melanoma staging, 
was evaluated in a phase 3 trial.
Methods
We evaluated outcomes in 2001 patients with primary cutaneous melanomas randomly 
assigned to undergo wide excision and nodal observation, with lymphadenectomy for 
nodal relapse (observation group), or wide excision and sentinel-node biopsy, with 
immediate lymphadenectomy for nodal metastases detected on biopsy (biopsy group).
Results
No significant treatment-related difference in the 10-year melanoma-specific survival 
rate was seen in the overall study population (20.8% with and 79.2% without nodal 
metastases). Mean (±SE) 10-year disease-free survival rates were significantly im-
proved in the biopsy group, as compared with the observation group, among patients 
with intermediate-thickness melanomas, defined as 1.20 to 3.50 mm (71.3±1.8% vs. 
64.7±2.3%; hazard ratio for recurrence or metastasis, 0.76; P = 0.01), and those with 
thick melanomas, defined as >3.50 mm (50.7±4.0% vs. 40.5±4.7%; hazard ratio, 0.70; 
P = 0.03). Among patients with intermediate-thickness melanomas, the 10-year mela-
noma-specific survival rate was 62.1±4.8% among those with metastasis versus 
85.1±1.5% for those without metastasis (hazard ratio for death from melanoma, 3.09; 
P<0.001); among patients with thick melanomas, the respective rates were 48.0±7.0% 
and 64.6±4.9% (hazard ratio, 1.75; P = 0.03). Biopsy-based management improved the 
10-year rate of distant disease–free survival (hazard ratio for distant metastasis, 0.62; 
P = 0.02) and the 10-year rate of melanoma-specific survival (hazard ratio for death 
from melanoma, 0.56; P = 0.006) for patients with intermediate-thickness melanomas 
and nodal metastases. Accelerated-failure-time latent-subgroup analysis was performed 
to account for the fact that nodal status was initially known only in the biopsy group, 
and a significant treatment benefit persisted.
Conclusions
Biopsy-based staging of intermediate-thickness or thick primary melanomas provides 
important prognostic information and identifies patients with nodal metastases 
who may benefit from immediate complete lymphadenectomy. Biopsy-based manage-
ment prolongs disease-free survival for all patients and prolongs distant disease–free 
survival and melanoma-specific survival for patients with nodal metastases from 
intermediate-thickness melanomas. (Funded by the National Cancer Institute, 
National Institutes of Health, and the Australia and New Zealand Melanoma Trials 
Group; ClinicalTrials.gov number, NCT00275496.)
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R egional node management in mel-anoma has remained controversial since Snow1 recommended elective complete 
lymphadenectomy for all patients with melanoma, 
regardless of whether there was clinical evidence 
of regional nodal metastases. However, routine 
elective lymphadenectomy exposes all patients to 
procedure-related complications and cannot bene-
fit the majority, who have no regional nodal metas-
tases. Multiple randomized trials have suggested a 
benefit of routine lymphadenectomy in at least 
some groups of patients with melanoma.2-6
Because of dissatisfaction with both elective 
lymphadenectomy and nodal observation, lym-
phatic mapping and sentinel-node biopsy were 
introduced for individualized management of 
regional lymph nodes.6-9 Sentinel-node biopsy 
is a minimally invasive, low-morbidity staging pro-
cedure performed with the use of blue dye and 
radiolabeled colloids. It identifies the first (i.e., 
sentinel) node or nodes in the regional basin that 
receive lymph from the primary melanoma site. 
Because the sentinel node is the initial site of re-
gional metastasis,10-14 its tumor status accurately 
predicts the tumor status of other nodes in the 
lymphatic basin. If focused pathological scrutiny of 
the sentinel node identifies no metastases, other 
regional nodes will probably also be negative.
The Multicenter Selective Lymphadenectomy 
Trial (MSLT-I) commenced in 1994 to determine 
whether sentinel-node biopsy could be used to 
identify patients with clinically occult nodal 
 metastases and whether immediate-completion 
lymphadenectomy yielded better outcomes than 
complete lymphadenectomy performed only when 
nodal recurrence was revealed during observation. 
Enrollment closed in 2002, after 2001 patients had 
been registered. The 5-year results of the third 
interim analysis, published in 2006,11 highlighted 
patients in the primary study group who had pri-
mary melanomas of intermediate thickness (de-
fined as 1.20 to 3.50 mm). We now report 10-year 
follow-up data for that group as well as for pa-
tients with thick primary melanomas (defined as 
>3.50 mm thick). We also report the results of a 
new accelerated-failure-time latent-subgroup analy-
sis of the treatment effect of sentinel-node biopsy.
Me thods
Trial Design
Criteria for enrollment in the MSLT-I included 
both Breslow thickness and Clark level (a mea-
sure of the depth of tumor penetration within 
the anatomical layers of the skin). Candidates 
for inclusion were patients who had localized 
cutaneous melanomas of Clark level III with a 
Breslow thickness of 1.00 mm or more or mela-
nomas of Clark level IV or V with any Breslow 
thickness. Patients with intermediate-thickness 
melanomas constituted the primary study group, 
because pretrial statistical modeling indicated 
that the timing of complete lymphadenectomy 
was most likely to affect survival in this group.15 
The results of a post hoc analysis of groups with 
melanomas of 1.00 to 4.00 mm in thickness 
were similar (see the Supplementary Appendix, 
available with the full text of this article at 
NEJM.org).
The study was conducted with the approval 
of the institutional review board or ethics com-
mittee at each of the participating institutions. 
All authors vouch for the accuracy and com-
pleteness of the data presented.
Patients
Eligible patients who provided written informed 
consent were randomly assigned to undergo wide 
excision of the primary melanoma plus sentinel-
node biopsy (biopsy group, 60% of patients) or 
wide excision plus postoperative nodal observa-
tion (observation group, 40%) (Fig. 1A). For exci-
sion of intermediate-thickness and thick mela-
nomas, margins of 2 to 3 cm were recommended, 
with adjustment permissible for anatomical or 
functional considerations. Patients in the observa-
tion group underwent delayed lymphadenectomy 
if nodal metastases developed during observa-
tion. Patients in the biopsy group underwent im-
mediate lymphadenectomy if metastases were 
detected in sentinel nodes stained with hema-
toxylin and eosin or immunohistochemically 
stained for S-100, HMB-45, and melanoma anti-
gen recognized by T cells (MART-1, also called 
MelanA [melanoma tumor antigen]).9,16,17 The 
presence of immunopositive cells of appropriate 
cytologic type in nodal parenchyma or in afferent 
Figure 1 (facing page). Trial Design, Enrollment,  
and Outcomes.
Panel A shows the design of the trial. Panel B shows 
enrollment and outcomes at 10 years of follow-up for 
patients with intermediate-thickness primary melano-
mas (1.20 to 3.50 mm) and those with thick primary 
melanomas (>3.50 mm).
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Stratification and randomization of all patients
60% of patients assigned to wide excision
and sentinel-node biopsy
40% of patients assigned to wide excision
and nodal observation
Follow-up for systemic recurrence and survival (10 yr)
Nodal recurrence:
Complete lympha-
denectomy
No nodal
recurrence:
Continued nodal 
observation
Sentinel-node positive:
Immediate complete
lymphadenectomy
Sentinel-node negative:
Nodal observation
1347 Had intermediate-thickness
primary melanomas
314 Had thick primary melanomas
814 Were assigned to sentinel-
node biopsy
770 (94.6%) Underwent biopsy
35 (4.3%) Underwent
 observation
8 (1.0%) Withdrew before
treatment
1 (0.1%) Was ineligible
533 Were assigned to nodal
observation
500 (93.8%) Underwent
 observation
22 (4.1%) Underwent biopsy
11 (2.1%) Withdrew before
treatment
186 Were assigned to sentinel-
node biopsy
173 (93.0%) Underwent biopsy
12 (6.5%)  Underwent
 observation
1 (0.5%) Was ineligible
128 Were assigned to nodal
observation
117 (91.4%)  Underwent
 observation
9 (7.0%) Underwent biopsy
2 (1.6%) Withdrew before
treatment
505 Completed the trial
133 Died from melanoma
47 Died from other causes
120 Were lost to follow-up
326 Completed the trial
103 Died from melanoma
25 Died from other causes
68 Were lost to follow-up
805 Were included
in the follow-up
522 Were included
in the follow-up
185 Were included
in the follow-up
126 Were included
in the follow-up
Nodal recurrence:
Complete lympha-
denectomy
No nodal
recurrence:
Continued nodal 
observation
1661 Patients underwent randomization:
10-yr follow-up
B
A
80 Completed the trial
68 Died from melanoma
19 Died from other causes
18 Were lost to follow-up
65 Completed the trial
43 Died from melanoma
9 Died from other causes
9 Were lost to follow-up
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lymphatic vessels was acceptable evidence of a 
nodal tumor, even if cells were identified by im-
munohistochemical analysis alone and even if 
only one such cell was identified. Nodal nevo-
cytes were identified by their morphologic fea-
tures, location, and characteristic immunophe-
notype (S-100 expression, MART-1 expression, 
and weak or no expression of HMB-45).
Patients in both groups were monitored post-
operatively by means of clinical examination, 
blood testing, and chest radiography, performed 
every 3 months during the first 2 years, every 
4 months during year 3, every 6 months during 
years 4 and 5, and then annually until year 10. 
Participating sites were permitted to use their 
routine follow-up procedure, which could include 
periodic positron-emission tomographic and com-
puted tomographic scanning, nodal ultrasonogra-
phy, and testing for melanoma markers such as 
S-100 and lactate dehydrogenase.
Statistical Analysis
For patients with intermediate-thickness or thick 
primary melanomas, randomization was strati-
fied according to Breslow thickness (1.20 to 1.79, 
1.80 to 3.50, or >3.50 mm) and primary tumor 
site (extremity or nonextremity) and was per-
formed in random permuted blocks of four, six, 
and eight patients.11 The primary end point was 
melanoma-specific survival (survival until death 
from melanoma). The secondary end points, de-
scribed previously,11,12 included disease-free surviv-
al, survival with tumor-positive or tumor-negative 
sentinel nodes, and the incidence of sentinel-
node metastases, as compared with the incidence 
of clinically detected nodal metastases. Follow-
up and survival were calculated from the date of 
randomization to the date of the last evaluation 
or death. Disease-free survival and distant dis-
ease–free survival were calculated from the date 
of randomization to the date of any melanoma 
recurrence within or beyond the primary tumor 
region, respectively. A false negative result of 
sentinel-node biopsy was defined as regional 
nodal recurrence in a patient whose sentinel 
nodes had been found to be tumor-free.
The initial sample size, 900 patients, for the 
group with intermediate-thickness melanomas was 
selected for 90% power with a 5% type I error 
rate. The underlying assumptions for the compu-
tation of sample size were based on historical data 
in the John Wayne Cancer Institute database.11,15 
After the second interim analysis, the sample 
size for the intermediate-thickness group was 
increased to 1200 patients, because the distribu-
tion of trial entrants was more skewed toward 
lower-risk patients than expected.11,15 The final 
study sample included 2001 patients, with 1347 
in the group with intermediate-thickness mela-
nomas, 340 in the group with thin melanomas 
(defined as <1.20 mm), and 314 in the group 
with thick melanomas; these sample sizes pro-
vided power to detect differences in the 10-year 
survival rate of 10 to 16 percentage points, de-
pending on the tumor-thickness category and 
primary tumor site.
The Kaplan–Meier method was used to esti-
mate mean 5-year and 10-year rates of melanoma-
specific and disease-free survival. P values for 
survival curves were derived from Wald tests for 
hazard ratios in the Cox proportional-hazards 
model. Baseline demographic, clinical, and patho-
logic characteristics were compared with the use 
of a t-test or chi-square test, and the Wilcoxon 
rank-sum test was used to compare numbers of 
tumor-involved nodes. We used SAS software, ver-
sion 9.2 (SAS Institute), for all analyses. A two-sided 
P value of 0.05 or lower was considered to indi-
cate statistical significance.
Comparisons of melanoma-specific and disease-
free survival were based on data from patients who 
underwent their assigned treatment. Results of par-
allel analyses performed according to the intention-
to-treat principle were consistent with those of the 
per-protocol analysis (see the Sup plementary Ap-
pen dix). Subgroup analyses included patients in 
the biopsy group for whom information on nodal 
status was available and patients in the observa-
tion group in whom clinically detectable nodal 
metastases developed. Because pathologic nodal 
status was initially known only in the biopsy 
group, there was concern about ascertainment 
bias relative to node-positive patients. In post hoc 
analyses, a latent-subgroup analytic method was 
developed to account for the possibility of such 
bias and to allow determination of treatment effect 
within the node-positive subgroups.18 In this analy-
sis, we used a semiparametric accelerated-fail-
ure-time mixture model with bootstrap methods 
to estimate variance. Performance of the analysis 
was corroborated in multiple simulations. The 
output of the analysis is a measure of treatment 
effect, which corresponds to an increase in sur-
vival time related to the experimental treatment.
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R esult s
Treatment Groups
Treatment groups were balanced with respect to 
primary tumor site, Clark level, Breslow thickness, 
ulceration, and age (Table S1 in the Supplementary 
Appendix). For the per-protocol analysis (Fig. 1B), 
1270 patients with intermediate-thickness pri-
mary melanomas could be evaluated (770 in the 
biopsy group and 500 in the observation group), 
as could 290 patients with thick primary melano-
mas (173 in the biopsy group and 117 in the ob-
servation group), and 232 patients with thin pri-
mary melanomas (141 in the biopsy group and 91 
in the observation group). Because of space con-
straints and event infrequency among patients 
with thin primary melanomas, data from this 
cohort are considered exploratory and are not re-
ported on in this article.
Survival Rates
Among all patients with intermediate-thickness 
melanomas (with or without nodal metastases) 
there was no significant treatment-related differ-
ence in the 10-year melanoma-specific survival 
rates; the mean (±SE) rate was 81.4±1.5% in the 
biopsy group and 78.3±2.0% in the observation 
group (hazard ratio for death from melanoma in 
the biopsy group, 0.84; 95% confidence interval 
[CI], 0.64 to 1.09; P = 0.18) (Fig. 2A). There was 
also no significant between-group difference in 
10-year melanoma-specific survival rates among 
patients with thick melanomas (Fig. 2B).
Ten-year disease-free survival rates were sig-
nificantly higher in the biopsy group than in the 
observation group. Among patients with inter-
mediate-thickness melanomas (Fig. 2C), the rate 
was 71.3±1.8% in the biopsy group as compared 
with 64.7±2.3% in the observation group (haz-
ard ratio for recurrence or metastasis, 0.76; 95% 
CI, 0.62 to 0.94; P = 0.01); among patients with 
thick melanomas (Fig. 2D), the respective rates 
were 50.7±4.0% and 40.5±4.7 (hazard ratio, 0.70; 
95% CI, 0.50 to 0.96; P = 0.03).
Prognostic Significance of the Sentinel Node
In the biopsy group, patients with sentinel-node 
metastases had poorer outcomes than did patients 
with tumor-free sentinel nodes. In the group of 
patients with intermediate-thickness melanomas, 
the 10-year melanoma-specific survival rate was 
62.1±4.8% among those with sentinel-node metas-
tases as compared with 85.1±1.5% among those 
with tumor-free sentinel nodes (hazard ratio for 
death from melanoma, 3.09; 95% CI, 2.12 to 4.49; 
P<0.001) (Fig. S1A in the Supplementary Ap pen-
dix)11; in the group of patients with thick mela-
nomas, the respective rates were 48.0±7.0% and 
64.6±4.9% (hazard ratio, 1.75; 95% CI, 1.07 to 
2.87; P = 0.03) (Fig. S1B in the Supplementary 
Appendix). In a multivariate analysis (Table 1), 
sentinel-node status was the strongest predictor 
of disease recurrence or death from melanoma.
Presence of Nodal Metastases
The frequency of nodal metastasis across all 
Breslow-thickness groups was 20.8%. Long-
term follow-up confirmed the similar rates of 
nodal metastases in the two treatment groups 
(Fig. 3A and 3B, and Table S1 in the Supplementary 
Ap pen dix). Of 500 patients in the observation 
group who had intermediate-thickness melano-
mas, 87 (17.4%) had nodal metastases at a me-
dian of 19.2 months (95% CI, 13.6 to 24.1) after 
randomization (Table S1A in the Supplementary 
Appendix); the estimated 10-year cumulative in-
cidence of nodal metastasis was 19.5% (Fig. 3A). 
Of 117 patients observed after wide excision of 
thick melanomas, 44 (37.6%) had nodal relapse 
at a median of 9.2 months (95% CI, 6.4 to 12.2) 
after randomization (Table S1B in the Sup ple-
men tary Appendix); the estimated cumulative in-
cidence of nodal metastases at 10 years was 41.4% 
(Fig. 3B).
Among the 770 patients in the biopsy group 
who had intermediate-thickness melanomas, 
sentinel nodes were identified in 765 (99.4%); 
metastases were identified in 122 of these pa-
tients (16.0%) (Table S1A in the Supplementary 
Appendix). Nodal metastases were detected dur-
ing observation in 31 of 643 patients (4.8%) with 
tumor-free sentinel nodes; thus, the proportion 
of patients with intermediate-thickness melano-
mas who had nodal metastases in the biopsy 
group was 20.0% (153 of 765 patients), and the 
estimated cumulative incidence of nodal metas-
tases at 10 years was 21.9% (Fig. 3A).
All 173 patients with thick melanomas in 
the biopsy group had sentinel nodes identified, 
and 57 (32.9%) had sentinel-node metastases 
(Table S1B in the Supplementary Appendix). 
Nodal metastases were subsequently detected 
in 12 of 116 patients (10.3%) with sentinel 
nodes that were initially tumor-free; thus, the 
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proportion of patients with thick melanomas 
who had nodal metastases in the biopsy group 
was 39.9% (69 of 173 patients), and the estimated 
cumulative incidence of nodal metastases at 
10 years was 42.0% (Fig. 3B).
Survival in Groups with Nodal Metastases
The distribution of prognostic factors among pa-
tients with nodal metastases did not differ sig-
nificantly between the two treatment groups, 
with the exception of age among patients with 
thick melanomas (Tables S1A and S1B in the Sup-
plementary Appendix).
Among patients with nodal metastases from 
intermediate-thickness melanomas, the 10-year 
melanoma-specific survival rate was 62.1±4.8% 
in the biopsy group as compared with 41.5±5.6% 
in the observation group (hazard ratio for death 
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Figure 2. Melanoma-Specific and Disease-free Survival, According to Study Group and Melanoma Thickness.
Plus–minus values are means ±SE for the estimated rate of survival at specified time points. OBS denotes nodal observation, and SNB 
sentinel-node biopsy.
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from melanoma, 0.56; 95% CI, 0.37 to 0.84; 
P = 0.006) (Fig. 3C). This treatment-related differ-
ence remained significant after patients with false 
negative sentinel nodes were included (10-year 
melanoma-specific survival rate, 56.0±4.3% in 
the biopsy group vs. 41.5±5.6% in the observa-
tion group; hazard ratio, 0.67; 95% CI, 0.46 to 
0.97; P = 0.04). A treatment-related difference 
was not seen for patients with thick melanomas 
(Fig. 3D): the 10-year melanoma-specific sur-
vival rate was 48.0±7.0% in the biopsy group and 
45.8±7.8% in the observation group (hazard ra-
tio, 0.92; 95% CI, 0.53 to 1.60; P = 0.78). The 
melanoma-specific survival rate among patients 
in whom same-basin nodal metastases devel-
oped after a negative result of sentinel-node bi-
opsy was similar to that among patients in 
whom nodal metastases developed during ob-
servation (Fig. 3C and 3D).
Among patients who did not have nodal me-
tastases (those in whom no tumor was found by 
sentinel-node biopsy or during clinical observa-
tion), there was no treatment-related difference 
in the 10-year melanoma-specific survival rate 
for patients with intermediate-thickness mela-
nomas (88.0±1.4% in the biopsy group and 
86.6±1.8% in the observation group; hazard ra-
tio for death from melanoma in the biopsy 
group, 0.89; P = 0.54) (Fig. 3C) or those with 
thick melanomas (69.8±5.0% in the biopsy group 
and 76.1±5.2% in the observation group; hazard 
ratio, 1.18; P = 0.61) (Fig. 3D).
Distant disease–free survival was significantly 
improved when patients with nodal metastases 
from intermediate-thickness melanomas received 
immediate rather than delayed lymphadenectomy 
(hazard ratio for distant metastasis, 0.62; 95% 
CI, 0.42 to 0.91, P = 0.02) (Fig. S2A in the Sup ple-
mentary Appendix). A similar benefit was not 
seen among patients with thick melanomas 
(hazard ratio, 0.96; 95% CI, 0.56 to 1.64, P = 0.88) 
(Fig. S2B in the Supplementary Appendix).
Latent-Subgroup Analysis
Latent-subgroup statistical methods were used to 
estimate the treatment effect of sentinel-node bi-
opsy with immediate lymphadenectomy in the 
subgroup of patients with nodal metastases.17 
Among patients with intermediate-thickness 
melanomas, both disease-free and distant dis-
ease–free survival were improved in the biopsy 
group; the estimated treatment effect on disease-
free survival was 1.17 (P<0.001), and the estimated 
effect on distant disease–free survival was 0.73 
(P = 0.04). For melanoma-specific survival, the 
estimated treatment effect was 0.68 (P = 0.05). 
These treatment effects on disease-free survival, 
distant disease–free survival, and melanoma-
specific survival indicate an increase in survival 
times by factors of 3.2, 2.1, and 2.0, respectively.
Discussion
A joint committee of the Society of Surgical 
Oncology and the American Society of Clinical 
Oncology recently issued an evidence-based 
Table 1. Multivariate Hazard Ratios for Disease Recurrence and Death among Patients with Intermediate-Thickness 
Melanoma Who Underwent Sentinel-Node Biopsy, According to Prognostic Indicator.
Prognostic Indicator Disease Recurrence Death from Melanoma
Hazard Ratio  
(95% CI) P Value
Hazard Ratio  
(95% CI) P Value
Sentinel-node status (positive vs. negative) 2.64 (1.92–3.64) <0.001 2.40 (1.61–3.56) <0.001
Breslow thickness (per 1-mm increase) 1.62 (1.31–2.01) <0.001 1.59 (1.21–2.09) <0.001
Ulceration (present vs. absent) 1.40 (1.04–1.89) 0.03 1.79 (1.24–2.58) 0.002
Site of melanoma
Arm or leg* 1.00 1.00
Trunk 1.42 (1.03–1.94) 0.03 1.91 (1.26–2.88) 0.002
Head or neck 1.20 (0.77–1.86) 0.42 1.19 (0.65–2.16) 0.58
Sex (male vs. female) 0.94 (0.70–1.26) 0.66 1.22 (0.82–1.79) 0.32
Age (per 1-yr increase) 1.01 (1.00–1.02) 0.07 1.01 (0.99–1.02) 0.33
Clark level (IV or V vs. III) 1.27 (0.94–1.71) 0.12 1.07 (0.74–1.54) 0.73
* This group served as the reference group.
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guideline that recommends sentinel-node biopsy 
for patients with intermediate-thickness melano-
mas and consideration of the procedure for pa-
tients with thick melanomas.19 Our current report, 
which provides the final long-term follow-up data 
from a randomized, international clinical trial of 
sentinel-node biopsy versus observation, augments 
the evidence base for the use of sentinel-node bi-
opsy in such patients.20-22
Previous MSLT-I reports showed the feasibility 
and accuracy of sentinel-node biopsy.7,10,11 A sen-
tinel node was identified in 99.4% of patients with 
intermediate-thickness melanomas. Our long-term 
results confirm that sentinel-node biopsy correctly 
determines the pathologic status of the nodal basin 
in 96% of cases and is the most powerful prognos-
tic indicator. Such prognostic information is par-
ticularly important in view of recently approved 
adjuvant therapy regimens and the continued need 
to evaluate new approaches to adjuvant therapy.23
These current, long-term data also confirm 
that sentinel-node–guided management protects 
patients from melanoma recurrence, particularly 
nodal recurrence. Although nodal metastases can 
usually be removed at the time of clinical presenta-
tion, such recurrences are associated with substan-
tially compromised quality of life and a signifi-
cantly increased risk of long-term morbidity after 
complete lymph-node dissection.24,25 For these rea-
sons, disease-free survival has been accepted as a 
valid end point for surgical trials, drug studies, and 
Food and Drug Administration approval.11,20,26,27
We did not see a significant survival advan-
tage for all patients with intermediate-thickness 
melanomas. This is unsurprising, because the 
overall event rates, and therefore the power of 
the study, were lower than anticipated. The rate 
of false negative biopsy results may have further 
obscured the therapeutic effect of the interven-
tion.13 Early in the trial, mapping was performed 
with the use of blue dye alone, and the study 
personnel had less technical experience than they 
did later in the study; these factors are linked to 
higher false negative rates than are expected cur-
rently. Prior analysis of data from this trial 
showed decreasing rates of false negative results 
with greater experience.13 Also, as with all trials 
of early nodal intervention, most patients in our 
trial did not have nodal metastases. The trial 
confirms that in patients without nodal metasta-
ses, nodal intervention provides critical prognos-
tic information but no therapeutic benefit.
These results confirm that for patients with 
intermediate-thickness melanomas who have 
clinically occult nodal metastases, early inter-
vention decreases the risk of nodal recurrence, 
distant metastases, and death from melanoma. 
Increases in distant disease–free survival and 
melanoma-specific survival were not seen among 
patients with thick melanomas. Although some 
patients with nodal metastases from thick mela-
nomas may benefit from lymphadenectomy, our 
findings suggest that the timing of that inter-
vention is not as critical as it is for patients with 
intermediate-thickness melanomas; this obser-
vation is consistent with the findings in studies 
from the era of elective lymph-node dissection.28 
The number of patients with thin melanomas in 
this trial was too small to permit conclusions 
about the therapeutic effect of biopsy-based 
treatment in such patients; this is an issue that 
remains unresolved.
A separate analysis of patients with node-
positive disease is justified by the obvious bio-
logic rationale (i.e., only patients with nodal 
disease can benefit from nodal intervention) and 
by the close similarity between the node-positive 
subgroups in the two treatment groups, espe-
cially with respect to several robust prognostic 
indicators: Breslow thickness, ulceration status, 
sex, and primary tumor site. The cumulative rates 
of nodal involvement in the two groups were also 
Figure 3 (facing page). Estimated 10-Year Incidence  
of Nodal Metastasis and Melanoma-Specific Survival, 
According to Study Group, Melanoma Thickness,  
and Presence or Absence of Nodal Recurrence.
Panels A and B show the cumulative incidence of nodal 
metastasis at 10 years among patients with intermedi-
ate-thickness melanomas and those with thick melano-
mas, respectively. Data are from the per-protocol anal-
ysis; patients who left the study or were lost to 
follow-up were excluded. In the biopsy group, nodal 
recurrence in patients whose sentinel nodes were neg-
ative for tumor (i.e., false negative biopsy results) was 
assessed. Plus–minus values are means ±SE for the 
estimated rate of nodal metastasis. The abbreviation 
neg. denotes negative, and pos. positive. Panels C and 
D show the probability of melanoma-specific survival 
(i.e., survival until death from melanoma) among pa-
tients with intermediate-thickness melanomas and 
those with thick melanomas, respectively. Numbers 
(1 –4) to the right of the survival curves refer to the 
numbered comparisons below each graph. Plus–minus 
values are means ±SE for the estimated probability of 
melanoma-specific survival.
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similar. This similarity refutes previous assertions 
regarding false positive sentinel nodes.29,30 Early in 
the follow-up period, the cumulative rate of nodal 
involvement was higher in the biopsy group than in 
the observation group, a difference that dwindled 
with increasing follow-up. Any remaining differ-
ences in the frequency of nodal metastasis may 
be accounted for by chance or by late nodal recur-
rences still pending in the observation group.31,32 
These data indicate that essentially all metastases 
detected by sentinel-node biopsy eventually would 
have become clinically evident if not removed.
Despite the consistent strength of the data 
from the MSLT-I, there has been some reluctance 
to accept the results of comparisons between 
node-positive patients in the biopsy group and 
those in the observation group, because of con-
cern about ascertainment bias. Latent-subgroup 
analysis methods were used to address this sta-
tistical consideration.
Latent-subgroup analysis is used when a char-
acteristic is immediately observable in one study 
group but not in the other.17,33 In the MSLT-I, 
sentinel-node status was known for the biopsy 
group but not for the observation group. Since a 
one-to-one relationship between sentinel-node 
metastases and eventual, clinically detected nodal 
recurrence cannot be guaranteed, standard sur-
vival analyses are potentially biased toward the 
biopsy group. In latent-subgroup analysis, a semi-
parametric accelerated-failure-time mixture model 
is used for the estimation of a biologic treatment 
effect. This recovers the ability to estimate a treat-
ment effect despite the inability to randomize or 
stratify on the basis of nodal status at the trial 
start. In addition, the semiparametric method 
requires fewer assumptions than would a para-
metric method. When applied to this final data set, 
latent-subgroup analysis showed a clear, signifi-
cant benefit of sentinel-node biopsy: a doubling 
of melanoma-specific and distant disease–free 
survival and a tripling of disease-free survival.
These long-term results clearly validate the use 
of sentinel-node biopsy in patients with interme-
diate-thickness or thick primary melanomas. The 
procedure provides accurate and important stag-
ing information, enhances regional disease con-
trol, and, among patients with nodal metastases, 
appears to improve melanoma-specific survival 
substantially.
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